Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3169324 | 1.00 | PDE4B (0.33) | PDE4BPDE7ASMN1; SMN2PIK3CACHRNB2 | |
| SCHEMBL13660351 | 0.93 | SMN1; SMN2 (0.34) | PDE4BPDE7ASMN1; SMN2PIK3CACHRNB2 | |
| SCHEMBL3175372 | 0.89 | POLB (0.39) | PDE4BPDE7ASMN1; SMN2 | |
| SCHEMBL3175361 | 0.89 | POLB (0.39) | PDE4BPDE7ASMN1; SMN2 | |
| SCHEMBL3178928 | 0.85 | KDM4E (0.36) | PDE4BPDE7ASMN1; SMN2 | |
| SCHEMBL3178920 | 0.85 | KDM4E (0.36) | PDE4BPDE7ASMN1; SMN2 | |
| SCHEMBL13660414 | 0.84 | SMN1; SMN2 (0.34) | PDE4BPDE7ASMN1; SMN2CHRNB2CHRNA4 | |
| SCHEMBL4755763 | 0.78 | PIK3CA (0.36) | PIK3CACHRNB2CHRNA4 | |
| SCHEMBL4755760 | 0.78 | PIK3CA (0.36) | PIK3CACHRNB2CHRNA4 | |
| SCHEMBL4755767 | 0.77 | CHRNB2 (0.34) | PIK3CACHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100008866-A1 | CIS-CYCLOHEXYL SUBSTITUTED PYRIMIDINONE DERIVATIVES | NEUROGEN CORPORATION (US) | 2010-01-14 | — | — | US | claimed |
| US-20100008866-A1 | CIS-CYCLOHEXYL SUBSTITUTED PYRIMIDINONE DERIVATIVES | NEUROGEN CORPORATION (US) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100008866-A1 | CIS-CYCLOHEXYL SUBSTITUTED PYRIMIDINONE DERIVATIVES | PIGS, GPR174, GPR17 | PDE4B 1345/4885PDE7A 374/4885SMN1; SMN2 2096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.